Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
Add more filters










Publication year range
1.
Hipertensión (Madr., Ed. impr.) ; 18(4): 165-170, mayo 2001. tab, graf
Article in Es | IBECS | ID: ibc-1006

ABSTRACT

Objetivo. Determinar si la farmacocinética de irbesartán en dosis única se altera significativamente tras la administración de hidróxido de aluminio y magnesio (Unimaalox®). Métodos. Estudio abierto, randomizado, de 3 vías de tratamiento, en el que se incluyeron 18 voluntarios sanos. Los días 1, 8 y 15 de tratamiento los voluntarios recibieron por vía oral y en ayunas uno de los siguientes tratamientos: irbesartán 300 mg, irbesartán 300 mg + 10 ml de Unimaalox® suspensión concomitantemente, o irbesartán 300 mg + 10 ml de Unimaalox® suspensión 2 horas antes de la administración de irbesartán. Las muestras sanguíneas se recogieron en los tiempos especificados en el protocolo y hasta 48 horas, tomando como tiempo 0 la administración de irbesartán. Las concentraciones plasmáticas de irbesartán se determinaron mediante HPLC utilizando una técnica validada con extracción en fase sólida. Resultados. No se hallaron diferencias estadísticamente significativas en cuanto a la concentración plasmática máxima (Cmáx) o área bajo la curva de las concentraciones plasmáticas hasta las 48 horas (AUC0-48) postadministración entre los distintos tratamientos administrados. En el caso del AUC extrapolada al infinito (AUC0- ), las diferencias halladas entre los distintos grupos de tratamientos fueron estadísticamente significativas (p = 0,038) cuando se comparó la administración de irbesartán sólo frente a irbesartán más Unimaalox® administrado en las 2 horas previas (p = 0,021). Sin embargo, el intervalo de confianza al 90 por ciento para AUC0- se situó entre 0,67 y 1,5. La mediana para el tiempo en alcanzar la Cmax (tmax) fue de 2,5 horas en todos los grupos de tratamiento. Conclusiones. Estos resultados sugieren que no hay interacción entre el hidróxido de aluminio y magnesio e irbesartán. Por tanto, no es necesario realizar un ajuste de la dosificación cuando se administran concomitantemente (AU)


Subject(s)
Adult , Female , Male , Middle Aged , Humans , Aluminum Hydroxide/pharmacology , Magnesium/pharmacology , Antacids/pharmacology , Biphenyl Compounds/pharmacokinetics , Antihypertensive Agents/pharmacokinetics , Biphenyl Compounds/blood , Biphenyl Compounds/therapeutic use , Antihypertensive Agents/blood , Antihypertensive Agents/therapeutic use
3.
Rev. esp. cardiol. (Ed. impr.) ; 54(2): 186-193, feb. 2001.
Article in Es | IBECS | ID: ibc-2041

ABSTRACT

Todo paciente que va a someterse a una intervención quirúrgica requiere una evaluación cardiovascular que establezca su riesgo quirúrgico. Por otro lado, una importante proporción de las muertes ocurridas durante la cirugía se deben a complicaciones cardiovasculares, muchas de las cuales se podrían evitar valorando correctamente el riesgo cardiológico de la intervención. La cirugía y la anestesia someten al paciente a situaciones de estrés durante el período perioperatorio, que obligan a que se establezca la capacidad del enfermo de responder a esas demandas, desaconsejando la cirugía si se considera que el riesgo es inasumible. Cada vez aumenta más la proporción de casos de cirugía mayor en pacientes de más de 65 años, con el consiguiente incremento de la comorbilidad cardiovascular, especialmente por el riesgo de infarto de miocardio, angina inestable e insuficiencia cardíaca perioperatoria. Seguidamente se establecen unas recomendaciones para la valoración cardiovascular del paciente cardiológico que va a someterse a una intervención quirúrgica no cardíaca (AU)


Subject(s)
Humans , Risk Factors , Postoperative Complications , Cardiovascular Diseases , Anesthesia
5.
Osteoporos Int ; 7(1): 59-64, 1997.
Article in English | MEDLINE | ID: mdl-9102065

ABSTRACT

The aim of this study was to generate standard curves for bone mineral density (BMD) in a Spanish population using dual-energy X-ray absorptiometry (DXA), at both lumbar spine and femoral neck sites. The total sample size was 2442 subjects of both sexes aged 20-80 years, stratified according to survival rates, demographic distribution by local regions and sex ratio in the Spanish population. Subjects with suspected conditions affecting bone metabolism or receiving any treatment affecting bone mineralization were excluded. The study was carried out in 14 hospitals and bone density measurements were performed, using a QDR/ 1000 Hologic device. In the female population, the highest value for lumbar spine BMD was found within the 30-39 years age group, being significantly lower after the age of 49 years. In the male population, the highest values for lumbar spine BMD are found one decade earlier than in the female population and become significantly lower after the age of 69 years. The highest values for femoral neck BMD in men and women was found in the 20-29 year age group. Values for femoral neck BMD in the female population become statistically lower after the age of 49 years, while in the male population this effect was seen after the age of 69 years. Values for femoral neck BMD were higher in men than women at all ages.


Subject(s)
Bone Density , Femur Neck/physiology , Lumbar Vertebrae/physiology , Absorptiometry, Photon , Adult , Aged , Aged, 80 and over , Aging/physiology , Female , Humans , Male , Middle Aged , Observer Variation , Reference Values , Reproducibility of Results , Sex Characteristics , Spain
8.
Rev Med Univ Navarra ; 34(2): 77-9, 1990.
Article in Spanish | MEDLINE | ID: mdl-2130425

ABSTRACT

A controlled double-blind clinical trial was performed comparing therapeutic efficacy of hidrosmin versus diosmin in patients suffering from chronic venous insufficiency with varicose symptomatology in the inferior limbs. Ten patients were treated with hidrosmin and other 10 with diosmin randomly. The controls carried out during the trial were as follows; basal control before the beginning of the trial and therapeutic controls on days 15, 30, 60 and 90 of the study. With that aim clinical examinations and different explorations were performed: physical exam, phlebography, electrocardiogram, ophthalmological examination and biochemical analyses (hemogram, globular sedimentation rate, platelet counts, etc.). The clinical therapeutic efficacy of hidrosmin in the treatment of chronic venous insufficiency of inferior limbs was superior to the diosmin in most of the studied parameters even though a lower posology was employed. From a clinical point of view the clinical improvement in the subjective symptomatology (heaviness, local tenderness, cramps, paresthesias, etc.) was very superior to the one obtained with the objective signs (phlebography, skin trophism, evolution of the edema, etc.). No significative adverse reactions appeared.


Subject(s)
Diosmin/analogs & derivatives , Diosmin/therapeutic use , Edema/drug therapy , Postphlebitic Syndrome/drug therapy , Varicose Veins/drug therapy , Venous Insufficiency/drug therapy , Adult , Aged , Chronic Disease , Diosmin/adverse effects , Double-Blind Method , Drug Tolerance , Female , Humans , Male , Middle Aged
9.
An Esp Pediatr ; 30(5): 359-62, 1989 May.
Article in Spanish | MEDLINE | ID: mdl-2667410

ABSTRACT

The articles published in 1985 in 9 journals (3 of Internal Medicine, 3 of Pediatrics and 3 of Clinical Pharmacology) are revised with the purpose of studying: a) Number of clinical trials published. b) Number of clinical trials published accomplished in children. Among the 533 trials published, 102 were done in children. The type of trial done is studied based on the methodology used, if healthy volunteers are included, if pharmacokinetics studies were done, the ages of the subjects, the number of subjects included, the sex and the way of obtaining the informed consent.


Subject(s)
Clinical Trials as Topic/methods , Drug Therapy , Pediatrics , Adolescent , Child , Child, Preschool , Evaluation Studies as Topic , Female , Humans , Infant , Infant, Newborn , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...